ALKS Q2 2018 Earnings — Alkermes plc Revenue & Financial Results | Market Cap Arena

ALKSAlkermes plc

$5B

Q2 2018 Earnings

Healthcare Biotechnology

Income Statement

Revenue

$305M+39.2% YoY

Gross Profit

$261M85.7% margin

Operating Income

-$102,000-0.0% margin

Net Income

-$33M-10.7% margin

EPS (Diluted)

$-0.21

QoQ Revenue Growth

+35.3%

Cash Flow

Operating Cash Flow

$32M

Free Cash Flow

$15M

Stock-Based Comp.

$31M

Balance Sheet

Total Assets

$1.8B

Total Liabilities

$593M

Stockholders' Equity

$1.2B

Cash & Equivalents

$156M

Year-over-Year Comparison

Metric	Current	Year Ago	Change
Revenue	$305M	$219M	+39.2%
Gross Profit	$261M	$179M	+45.9%
Operating Income	-$102,000	-$45M	+99.8%
Net Income	-$33M	-$43M	+24.1%

Revenue Segments

Vivitrol

$76M69%

Aristada

$34M31%